DOCSLIB.ORG

Wo 2008/134712 A2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wo 2008/134712 A2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 6 November 2008 (06.11.2008) WO 2008/134712 A2 (51) International Patent Classification: Not classified [US/US]; 27 Armand Place, Ridgefield, CT 06877 (US). MCLAUGHLIN, Ronald, P. [US/US]; 115 Howard, (21) International Appbttrerlication Number: PCT/US2008/061992 Reading, MA 01867 (US). BEDFORD, Susan, Eilidh [GB/US]; 150 Aldershot Lane, Carlisle, MA 01741 (US). (22) International Filing Date: 30 April 2008 (30.04.2008) LI, Zhi [CN/US]; 17173 West Bernardo Drive Unit 203, (25) Filing Language: English San Diego, CA 92127 (US). (26) Publication Language: English (74) Agents: FITZPATRICK, Joseph, M. et al; Fitzpatrick, (30) Priority Data: Cella, Harper & Scinto, 30 Rockefeller Plaza, New York, 60/914,873 30 April 2007 (30.04.2007) US NY 10112-3801 (US). (71) Applicant (for all designated States except US): LIVING (81) Designated States (unless otherwise indicated, for every PROOF, INC. [US/US]; 6 1 Rogers Street, Cambridge, kind of national protection available): AE, AG, AL, AM, MA 02142 (US). AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (72) Inventors; and EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, (75) Inventors/Applicants (for US only): YU, Betty [US/US]; IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, 57 Reservoir Street, Unit 2, Cambridge, MA 02138 LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, (US). NASHAT, Amir [US/US]; 100 Boulder Road, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, Newton, MA 02459 (US). ANDERSON, Daniel, Griffith PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, [US/US]; 28 Red Oak Drive, Sudbury, MA 01776 (US). SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, PUERTA, David, Thomas [US/US]; 29 Cleveland Street, ZA, ZM, ZW Melrose, MA 02176 (US). ADAMS, Benjamin [US/US]; 42 Pearl Street, Cambridge, MA 02139 (US). CLARK, (84) Designated States (unless otherwise indicated, for every Scott [US/US]; 107 Quirico Drive, Pittsfield, MA 01201 kind of regional protection available): ARIPO (BW, GH, (US). KIM, Yushan [US/US]; 324 Hurley Street Apt. 2, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, Cambridge, MA 02141 (US). SPENGLER, Eric, George ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), [Continued on next page] (54) Title: USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE Figure 1. Appearance of Telangiectasia: Significant difference from placebo at 16 weeks * p-value < 0 1 Timepoint * p-value < 0 05 (57) Abstract: The application of matrix metalloproteinase (MMP) inhibitors to the skin inhibits the degradation of proteins found in the skin including collagen, elastin, and other basement membrane and extracellular matrix protein. MMP inhibitors may be used in both cosmetic compositions and pharmaceutical compositions for application to skin. MMP inhibitors are formulated with a cos metically suitable vehicle or pharmaceutically acceptable excipient for application to the skin as creams, lotions, ointments, solutions, face masks, etc. As cosmetics, the inventive MMP inhibitor compositions are applied to the skin to prevent or reduce the appearance of wrinkles, pigmentation changes, loss of elasticity, or other effects associated with aging or sun damage. As pharmaceuticals, the inventive MMP inhibitor compositions may also be applied to the skin to treat or prevent a skin disease (e.g., proliferative disease, inflammatory disease). European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, Published: FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, — without international search report and to be republished NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, upon receipt of that report CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). USE OF MATRIXMETALLOPROTEINASEINHIBITORS IN SKIN CARE Related Applications [0001] The present invention claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application, USSN 60/914,873, filed April 30, 2007, which is incorporated herein by reference. Background of the Invention [0002] The skin is the largest organ of the human body and extends over the entire body. The skin functions primarily to protect us from the outside world. The skin also functions to regulate the temperature of the body, protects the body from harmful UV rays, provides a defense against pathogens, stores fat, provides the sense the touch, excretes waste, synthesizes vitamin D, and provides cushioning and attachment. In protecting us from the outside world, the skin is constantly exposed to harsh temperatures, sunlight, dirt, dust, wind, chemicals, pathogens, and other insults. In addition, the skin is routinely subjected to washing and shaving. [0003] Skin is composed of two major layers: the epidermis and the underlying dermis, which are distinct in terms of their architecture, physiology, and function. The epidermis is a stratified epithelium composed of four layers: the stratum basale, stratum spinosum, stratum granulosum, and the outermost stratum corneum. The stratum basale contains a single layer of cuboidal keratinocytes attached to a basement membrane. Above this layer is the spinous layer, characterized by presence of numerous desmosomes. The stratum granulosum overlies the stratum spinosum and consists of keratinocytes that contain basophilic granules of keratohyalin as well as lamellar granules in the intercellular compartment. The stratum corneum is the most superficial layer and is composed of anucleated, flattened, fully keratinized cells (corneocytes) fused together to form a plate-like structure. The intercellular space is occupied by ordered lipid lamellae that contain specialized proteins and lipids, such as ceramides, fatty acids, and cholesterols, which are secreted from lamellar bodies in the stratum granulosum. The resulting "bricks and mortar" structure provides the stratum corneum with the ability to perform its protective and moisture retaining functions. The thickness of the epidermis ranges from about 75 to 150 µm except on the soles and palms, where it is about 0.4 to 0.6 mm. The dermoepidermal junction (DEJ) is an undulating basement membrane composed primarily of collagen that separates the epidermis from the dermis. [0004] The dermis is a dense, fibroelastic connective tissue that lies beneath the epidermis and provides a strong and flexible supporting layer. It is composed of cells (e.g., fibroblasts), ground substance, and a fibrous network containing collagenous and elastic fibers and also contains blood vessels, nerves, hair follicles, smooth muscle, glands and lymphatic tissue. Collagen, primarily types I, III, V, and VI, forms the majority of the fibrous component, making up about 75% of the dry weight of the dermis and imparting firmness and tensile strength. [0005] The dermis can be divided into two regions. The papillary dermis conforms to the shape of the overlying epidermis. The reticular dermis lies below the papillary dermis and forms the majority of the dermal layer, giving it most of its elasticity and strength. Elastic fibers of the papillary dermis are oriented parallel (elaunin fibers) or perpendicular (oxytalan fibers) to the DEJ and are thinner than the elastic fibers of the reticular dermis. Oxytalan fibers lack the elastin core while elaunin fibers contain a small amount of elastin. Mature elastin fibers are found primarily arranged in bundles in the reticular dermis and measure about 1-3 µm in diameter. [0006] Aging and exposure to environmental insults affect the appearance and structure of the skin. Sun-protected, naturally aged skin exhibits epidermal and dermal thinning, fragility, and fine, shallow wrinkles. There is a loss of elastic fibers in the papillary dermis, and collagen fibers become increasingly dense and more randomly oriented. Exposure to ultraviolet radiation from the sun accelerates and alters the degenerative processes associated with aging, resulting in a constellation of changes collectively known as photodamage. As much as 80% of facial aging may well be attributable to sun exposure. Photodamaged skin is characterized by loss of elasticity, deep wrinkles, increased roughness and dryness, and altered pigmentation (age spots). The skin may assume a leathery, thickened appearance characterized by deep furrows. [0007] Many individuals desire to preserve a youthful appearance. At the same time, tanned skin is considered attractive and outdoor recreational activities are popular, resulting in significant sun exposure and consequent photodamage to skin. Various approaches have been developed or are under investigation to reduce the visible signs of photodamage (Stern, R., N. Engl. J. Med, 350:1526-1534, 2004). Use of sunscreens can help to prevent further damage. Topical retinoids (vitamin A derivatives) can reduce the severity of photoaging (U.S. Patent 4,877,805; incorporated herein by reference). It has been proposed to treat the skin with compositions containing inhibitors of collagenase or elastase (U.S. Patents 5,614,489; 6,884,425; each of which is incorporated herein by reference). Chemical peels, which involve application of a variety of different chemical compounds to skin, result in temporary improvement in the appearance of photodamaged skin in some individuals. Microdermabrasion and laser resurfacing are other alternatives. Injection of botulinum toxin (e.g., Botox®) has gained popularity as a means of reducing furrows caused by muscle hypertonicity. Skin fillers such as bovine collagen and hyaluronic acid are used for soft tissue augmentation to reduce the appearance of, or to treat deep wrinkles. [0008] Such factors as exposure to the sun contribute to the premature aging of skin contributing to the formation of lines and wrinkles, skin dryness, skin fading, roughness, hyperpigmentation, age spots, and loss of elasticity. The physiological and pathological degradation of the connective tissue component of the skin by proteases from resident cells contributes to the loss of elasticity of the skin.
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • PC22 Doc. 22.1 Annex (In English Only / Únicamente En Inglés / Seulement En Anglais)
    Original language: English PC22 Doc. 22.1 Annex (in English only / únicamente en inglés / seulement en anglais) Quick scan of Orchidaceae species in European commerce as components of cosmetic, food and medicinal products Prepared by Josef A. Brinckmann Sebastopol, California, 95472 USA Commissioned by Federal Food Safety and Veterinary Office FSVO CITES Management Authorithy of Switzerland and Lichtenstein 2014 PC22 Doc 22.1 – p. 1 Contents Abbreviations and Acronyms ........................................................................................................................ 7 Executive Summary ...................................................................................................................................... 8 Information about the Databases Used ...................................................................................................... 11 1. Anoectochilus formosanus .................................................................................................................. 13 1.1. Countries of origin ................................................................................................................. 13 1.2. Commercially traded forms ................................................................................................... 13 1.2.1. Anoectochilus Formosanus Cell Culture Extract (CosIng) ............................................ 13 1.2.2. Anoectochilus Formosanus Extract (CosIng) ................................................................ 13 1.3. Selected finished
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Real Scientists Answer Your Beauty Questions
    Real Scientists Answer Your Beauty Questions Real Scientists Answer Your Beauty Questions edited by Sarah Bellum brains publishing Brains Publishing – New York, Chicago Copyright © 2008 by Brains Publishing All rights reserved. Published in the United States by Brains Publishing. www.brainspublishing.com The authors have attempted to make this book as accurate and up to date as possible, but it may contain errors, omissions, or material that is out of date at the time you read it. Neither the author nor publisher has any legal responsibility or liability for errors, omissions, out-of-date material, or the reader’s application of the advice contained in this book ISBN: 978-0-9802173-4-6 Printed in the United States of America First Edition For Beauty Brainiacs everywhere ... Real Scientists Answer Your Beauty Questions Table of Contents Who are the Beauty Brains viii What’s the Purpose of The Beauty Brains? ix Section I Hair Chapter 1 Hair Products and how they work The shampoo secret companies don’t want you to know 1 Is Paul Mitchell making your hair break 3 Is Ojon Restorative Treatment any good 5 Two natural oils that make your hair shiny and strong 7 Is Pantene good or bad for my hair 8 Are salon products in stores the same as those in salons 10 Do curling shampoos really work 11 Chapter 2 Tips on Caring for Your Hair Drying dilemma – What’s the best way to dry your hair 14 Three simple secrets to save your scalp 16 Want shiny hair? Avoid the dirty dozen 17 How to tell if a dandruff shampoo will really work 19 You don’t have to use
    [Show full text]
  • B DÉCISION DE LA COMMISSION Du 8 Mai 1996 Portant
    1996D0335 — FR — 09.02.2006 — 001.001 — 1 Ce document constitue un outil de documentation et n'engage pas la responsabilité des institutions ºB DÉCISION DE LA COMMISSION du 8 mai 1996 portant établissement d'un inventaire et d'une nomenclature commune des ingrédients employés dans les produits cosmétiques (Texte présentant de l'intérêt pour l'EEE) (96/335/CE) (JO L 132 du 1.6.1996, p. 1) Modifiée par: Journal officiel no page date ºM1 Décision de la Commission 2006/257/CE, du 9 février 2006 L 97 1 5.4.2006 1996D0335 — FR — 09.02.2006 — 001.001 — 2 ¼B DÉCISION DE LA COMMISSION du 8 mai 1996 portant établissement d'un inventaire et d'une nomenclature commune des ingrédients employés dans les produits cosmétiques (Texte présentant de l'intérêt pour l'EEE) (96/335/CE) LA COMMISSION DES COMMUNAUTÉS EUROPÉENNES, vu le traité instituant la Communauté européenne, vu la directive 76/768/CEE du Conseil, du 27 juillet 1976, concernant le rapprochement des législations des États membres relatives aux produits cosmétiques (1), modifiée en dernier lieu par la directive 95/34/CE de la Commission (2), et notamment son article 5 bis et son article 7 para- graphe 2, après consultation du comité scientifique de cosmétologie, considérant que l'inventaire des ingrédients employés dans les produits cosmétiques doit comprendre une partie relative aux matières premières parfumantes et aromatiques et une autre relative aux autres substances; considérant que cet inventaire doit contenir des informations sur l'iden- tité de chaque ingrédient, à savoir notamment les dénominations chimi- ques, INCI (ex-CTFA), Ph.
    [Show full text]
  • Dermalogica Ingredients
    Dermalogica Ingredients Caprylic/Capric Triglyceride, Prunus Armeniaca (Apricot) Kernel Oil, PEG-40 Sorbitan Peroleate, Tocopheryl Acetate, Borago Officinalis Seed Oil, Aleurites Moluccana Seed Oil, Oryza Sativa (Rice) Bran Oil, Solanum Lycopersicum (To- mato) Extract, Tocopherol, Helianthus Annuus (Sunflower) Seed Oil, Carthamus Tinctorius (Safflower) Seed Oil, Cetyl Ethylhexanoate, C12-15 Alkyl Benzoate, Decyl Olive Esters, Dicaprylyl Carbonate, Citral, Limonene, Linalool, Citrus Grandis (Grapefruit) Peel Oil, Lavandula Hybrida Oil, Cymbopogon Schoenanthus Oil, Citrus Aurantium Dulcis (Orange) Oil, Lavandula Angustifolia Dermalogica PreCleanse (Lavender) Oil, Citrus Nobilis (Mandarin Orange) Peel Oil, Isopropylparaben, 5.1oz/150ml-666151010611 Isobutylparaben, Butylparaben. Water/Aqua/Eau, Carthamus Tinctorius (Safflower) Seed Oil, Kaolin, Disodium Cocoamphodipropionate, Butylene Glycol, Glyceryl Stearate, Pentylene Glycol, Sorbitan Oleate, Illite, Melissa Officinalis Leaf Extract, Sodium Magnesium Silicate, Malva Sylvestris (Mallow) Flower/Leaf/Stem Extract, Cucumis Sativus (Cucumber) Fruit Extract, Sambucus Nigra Flower Extract, Arnica Montana Flower Extract, Parietaria Officinalis Extract, Nasturtium Officinale Flower/Leaf Extract, Arctium Lappa Root Extract, Salvia Officinalis (Sage) Leaf Extract, Citrus Medica Limonum (Lemon) Fruit Extract, Hedera Helix (Ivy) Leaf/Root Extract, Saponaria Officinalis Leaf/ Root Extract, Ascorbyl Palmitate, Tocopherol, Cetyl Dermalogica Dermal Clay Alcohol, Stearyl Alcohol, Sorbitan Trioleate, Menthol,
    [Show full text]
  • Household Product Delivering Warming And/Or Tingling Sensations
    (19) TZZ¥ _¥¥¥ T (11) EP 3 219 333 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.09.2017 Bulletin 2017/38 A61L 9/04 (2006.01) A61Q 13/00 (2006.01) C11B 9/00 (2006.01) (21) Application number: 17157672.1 (22) Date of filing: 23.02.2017 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • WARR, Jonathan GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 75017 Paris (FR) PL PT RO RS SE SI SK SM TR • PONCELET, Johan Designated Extension States: 75017 Paris (FR) BA ME • FRASER, Stuart Designated Validation States: Little Neston, Cheshire CH64 4DH (GB) MA MD (74) Representative: Mena, Sandra et al (30) Priority: 24.02.2016 EP 16305219 Cabinet Beau de Loménie 158 rue de l’Université (71) Applicant: Takasago International Corporation 75340 Paris Cedex 07 (FR) Tokyo 144-8721 (JP) (54) HOUSEHOLD PRODUCT DELIVERING WARMING AND/OR TINGLING SENSATIONS (57) The present invention relates to a household toxide, 2-isopropenyl-5-methyl-5-vinyltetrahydrofuran product comprising a fragrance composition, said fra- and isopulegol. In particular, the household product of grance composition comprising a chemaesthethic agent the invention is an air freshener dispenser device, a floor selected from the group consisting of: vanillyl ethyl ether, cleaner, a kitchen or bathroom surface cleaner, a toilet vanillyl n-propyl ether, vanillyl isopropyl ether, vanillyl rim block, or a toilet cistern block. butyl ether, elemol, elemicin, lime oxide, ocimene quin- EP 3 219 333 A2 Printed by Jouve, 75001
    [Show full text]
  • Diccionario Del Sistema De Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS
    DIRECCION GENERAL DE MEDICAMENTOS, INSUMOS Y DROGAS - DIGEMID EQUIPO DE ASESORIA - AREA DE CATALOGACION Diccionario del Sistema de Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS CODIGO DESCRIPCION ATC EN CASTELLANO DESCRIPCION ATC EN INGLES FUENTE A TRACTO ALIMENTARIO Y METABOLISMO ALIMENTARY TRACT AND METABOLISM ATC OMS A01 PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01A PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01AA Agentes para la profilaxis de las caries Caries prophylactic agents ATC OMS A01AA01 Fluoruro de sodio Sodium fluoride ATC OMS A01AA02 Monofluorfosfato de sodio Sodium monofluorophosphate ATC OMS A01AA03 Olaflur Olaflur ATC OMS A01AA04 Fluoruro de estaño Stannous fluoride ATC OMS A01AA30 Combinaciones Combinations ATC OMS A01AA51 Fluoruro de sodio, combinaciones Sodium fluoride, combinations ATC OMS A01AB Antiinfecciosos y antisépticos para el tratamiento oral local Antiinfectives and antiseptics for local oral treatment ATC OMS A01AB02 Peróxido de hidrógeno Hydrogen peroxide ATC OMS A01AB03 Clorhexidina Chlorhexidine ATC OMS A01AB04 Amfotericina B Amphotericin B ATC OMS A01AB05 Polinoxilina Polynoxylin ATC OMS A01AB06 Domifeno Domiphen ATC OMS A01AB07 Oxiquinolina Oxyquinoline ATC OMS A01AB08 Neomicina Neomycin ATC OMS A01AB09 Miconazol Miconazole ATC OMS A01AB10 Natamicina Natamycin ATC OMS A01AB11 Varios Various ATC OMS A01AB12 Hexetidina Hexetidine ATC OMS A01AB13 Tetraciclina Tetracycline ATC OMS A01AB14 Cloruro de benzoxonio
    [Show full text]
  • Jewels Cosmetics Ingredients
    Jewels Cosmetics Ingredients Volcanic Recovery Activating Serum Aqua, Glycerin, Polysorbate 20, Phenoxyethanol, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Glyceryl Acrylate/Acrylic Acid Copolymer, Parfum, Squalane, Caprylyl Glycol, Butylene Glycol, Ethylhexylglycerin, Hexylene Glycol, Propylene Glycol, Panthenol, Polysorbate 60, Ethylhexyl Palmitate, Sorbitan Isostearate, Diamond Powder, Volcanic Ash, Tetrasodium Edta, Carbomer, Chamomilla Recutita Flower Extract, Salvia Officinalis Leaf Extract, Limonene, Phospholipids, Xanthan Gum, Palmitoyl Oligopeptide, Palmitoyl-tetrapeptide-70, Tripeptide-29, Acetyl hexapeptide-30, Gardenia Jasminoides Meristem Cell Culture, Hydroxypropyl Methylcellulose, Pullulan, Porphyridium Cruentum Extract, Leontopodium Alpinum Callus, Ascorbyl Palmitate, Butylphenyl Methylpropional, Silica Dimethyl Silylate, Alpha-Isomethyl Ionone, Pentylene Glycol, Citral, Salicylic Acid, Retinyl Palmitate, Sorbic Acid, Isoeugenol, Sodium Hyaluronate, Tocopheryl Acetate, Citronellol, Geraniol. Volcanic Hydration Cream Aqua, Glycerin, Cyclomethicone, Dimethicone, Butylene Glycol, Peg-240/Hdi Copolymer Bis-Decyltetradeceth-20 Ether, Phenoxyethanol, Glyceryl Stearate, Peg-100 Stearate, Xanthan Gum, Parfum, Ethylhexylglycerin, Panthenol, Allantoin, Disodium Edta, Diamond Powder, Volcanic Ash, Potassium Laurate, Tocopherol, Palmitoyl Oligopeptide, Palmitoyl-Tetrapeptide-70, Tripeptide-29, Acetyl Hexapeptide-30, Gardenia Jasminoides Meristem Cell Culture, Hydroxypropyl Methylcellulose, Pullulan, Porphyridium
    [Show full text]
  • Salon Sized Haircare Ingredients
    Salon Sized Haircare Ingredients ABBA Pure Color Protect Shampoo 33.8oz/1000ml Aqua (Water) (Eau), Sodium Lauroyl Methyl Isethionate, Cocamidopropyl Betaine, PEG-150 Pentaerythrityl Tetrastearate, Glycerin, Polyquaternium-10, Glycol Stearate, Glycol Distearate, PEG-6 Caprylic/Capric Glycerides, Disodium EDTA, Cocos Nucifera (Coconut) Oil, Hydrolyzed Quinoa, Hydrolyzed Barley Protein, Hydrolyzed Soy Protein, Salvia Officinalis (Sage) Oil, Salvia Officinalis (Sage) Leaf Extract, Parfum (Fragrance), Limonene, Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde, Phenoxyethanol, Methylisothiazolinone Alterna Bamboo UV+ Rehab Deep Hydration Water (Aqua), Cetearyl Alcohol, Cetyl Alcohol, Stearamidopropyl Masque 16.9oz/500ml Dimethylamine, Glycerin, Cetyl Esters, Cetrimonium Chloride, Cyclopentasiloxane, Behentrimonium Methosulfate, Butyrospermum Parkii (Shea) Butter, Helianthus Annuus (Sunflower) Seed Oil, Polysilicone-15, Citrullus Ianatus (Kalahari Watermelon) Seed Oil, Helianthus Annuus (Sunflower) Seed Extract, Quaternium 95, Propanediol, Ceteareth-20, Phospholipids, Panthenol, Moringa Pterygosperma Seed Oil, Dimethiconol, Polysorbate 60, Polyquaternium- 10, Caprylic/Capric Triglyceride, Butylene Glycol, Fragrance (Parfum), Behentrimonium Chloride, Wasabia Japonica Leaf Extract, Silanetriol Melaninate, Tocopheryl Acetate, Bambusa Vulgaris Extract, Lecithin, Phyllostachis Bambusoides Juice, Saccharomyces/Copper Ferment, Superoxide Dismutase, Ethylhexyl Methoxycinnamate, Retinyl Palmitate, Hydrogenated Coco-Glycerides, Sucrose Laurate, Octocrylene,
    [Show full text]
  • WO 2016/204959 Al 22 December 2016 (22.12.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/204959 Al 22 December 2016 (22.12.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/06 (2006.01) A61K 31/14 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/44 (2006.01) A61K 31/155 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/00 (2006.01) A01P 1/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A0 33/12 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 16/034747 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 27 May 2016 (27.05.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/182,034 19 June 2015 (19.06.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/3 19,449 7 April 2016 (07.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/326,150 22 April 2016 (22.04.2016) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/338,995 19 May 2016 (19.05.2016) US LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: GLOBAL HEALTH SOLUTIONS, INC.
    [Show full text]
  • Cosmetovigilance in the Netherlands Trend Report 2012 - 2013
    Cosmetovigilance in The Netherlands Trend report 2012 - 2013 RIVM Letter Report 090128001/2013 L. de Wit-Bos et al. National Institute for Public Health and the Environment P.O. Box 1 | 3720 BA Bilthoven www.rivm.com Cosmetovigilance in The Netherlands Trend report 2012 - 2013 RIVM Letter report 090128001/2013 L. de Wit-Bos et al. RIVM Letter report 090128001 Colophon © RIVM 2014 Parts of this publication may be reproduced, provided acknowledgement is given to: National Institute for Public Health and the Environment, along with the title and year of publication. L. de Wit-Bos, RIVM M.W. Kooi, RIVM F.C. Bourgeois, RIVM T.F. van Gorcum, RIVM M.I. Bakker (project manager), RIVM Contact: Martine Bakker Centre for Safety of Substances and Products [email protected] This investigation has been performed by order and for the account of the Netherlands Food and Product Safety Authority, within the framework of Kennisvraag 09.01.28 Page 2 of 49 RIVM Letter report 090128001 Rapport in het kort Huidklachten door cosmetische producten Trendrapportage 2012 – 2013 Cosmetica zijn in principe veilig, maar kunnen soms huidklachten veroorzaken, zoals roodheid en jeuk. Het RIVM beheert een systeem waarin deze klachten en andere overgevoeligheidsreacties na gebruik van cosmetica kunnen worden geregistreerd (CESES, Consumer Exposure Skin Effects and Surveillance). Net als in voorgaande jaren zijn dergelijke klachten in 2012-2013 vooral gemeld na het gebruik van haarproducten, huidverzorgingsproducten en make-up. De klachten doen zich vooral voor bij producten die bedoeld zijn voor gebruik op of rond de ogen. Daarnaast hebben relatief veel kappers contacteczeem op de handen na het gebruik van haarproducten op hun werk.
    [Show full text]